Jaguar health subsidiary napo pharmaceuticals signs license agreement with its italian subsidiary, napo eu s.p.a., to develop and commercialize crofelemer and lechlemer in europe

Per the terms of the agreement, napo pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of napo eu and dragon spac s.p.a. and is eligible to receive additional payments related to milestones, royalties, and product transfers napo eu's initial focus is on accelerated conditional approval for orphan disease: short bowel syndrome with intestinal failure san francisco, ca / accesswire / august 19, 2021 / napo pharmaceuticals, inc. (napo), the wholly owned us subsidiary of jaguar health, inc. (nasdaq:jagx), today announced the signing of a license agreement with napo's italian subsidiary, napo eu s.p.a.
JAGX Ratings Summary
JAGX Quant Ranking